CYP2C19 Genetic Variants and Major Depressive Disorder: A Systematic Review

Larissa Sousa Silva Bonasser,Calliandra Maria de Souza Silva,Caroline Ferreira Fratelli,Bruna Rodrigues Gontijo,Juliana Moura Alves Seixas,Livia Cristina Lira de Sá Barreto,Izabel Cristina Rodrigues da Silva

DOI: https://doi.org/10.3390/ph17111461

IF: 4.6

2024-11-01

Pharmaceuticals

Abstract:Major depressive disorder (MDD) affects over 300 million people globally and has a multifactorial etiology. The CYP2C19 enzyme, involved in metabolizing certain antidepressants, can influence treatment response. Following the PRISMA protocol and PECOS strategy, this systematic review assessed the variation in common CYP2C19 gene variants' frequencies across populations with MDD, evaluating their impact on clinical characteristics and treatment response. We comprehensively searched five databases, identifying 240 articles, of which only nine within the last decade met our inclusion criteria. Except for one study that achieved 74.28% of STROPS items, the rest met at least 75% of GRIPS and STROPS guidelines for quality and bias risk assessment. The CYP2C19's *1 allele, the *1/*1 genotype, and the NM phenotype, considered as references, were generally more frequent. Other CYP2C19 polymorphism frequencies exhibit significant variability across different populations. Some studies associated variants with MDD development, a more extended history of depression, prolonged depressive episodes, and symptom severity, while others reported no such association. Some studies confirmed variants' effects on escitalopram and citalopram metabolism but not that of other drugs, such as sertraline, venlafaxine, and bupropion. Treatment tolerability and symptom improvement also varied between studies. Despite some common findings, inconsistencies highlight the need for further research to clarify the role of these polymorphisms in MDD and optimize treatment strategies.

pharmacology & pharmacy,chemistry, medicinal